4:56 PM ET
10-K
Financial Results
Lunai Bioworks FY 2026 Results: Net Loss of $3.56M, Loss Narrows
Lunai Bioworks Inc. (formerly Renovaro Biosciences) is navigating a complex regulatory landscape for its AI-driven diagnostic and therapeutic platforms, including compliance with the EU AI Act and shifting US federal oversight. The company is currently advancing pre-clinical candidates RENB-DC-11 for solid tumors and BioS_831 for epilepsy, while facing significant competition from larger pharmaceutical entities.
- Key figure
- Net loss $3.56M